首页>
外国专利>
Mutations in KIT confer imatinib resistance in gastrointestinal stromal tumors
Mutations in KIT confer imatinib resistance in gastrointestinal stromal tumors
展开▼
机译:KIT突变赋予胃肠道间质瘤伊马替尼耐药
展开▼
页面导航
摘要
著录项
相似文献
摘要
The present invention relates to methods and compositions concerning resistance to a drug for cancer comprising aberrant KIT signal, such as aberrant KIT sequence or expression. In a specific embodiment, the cancer is also initially responsive to imatinib therapy, such as in gastrointestinal stromal tumors (GISTs). In particular embodiments, a mutation in a KIT polynucleotide confers resistance to imatinib treatment, and in specific embodiments the exemplary mutation is at 1982T→C. Thus, the invention provides a means to adjust for or circumvent the resistance to imatinib drug treatment.
展开▼